News & Updates

Show Multimedia Only

Adding durvalumab upfront to chemo ups long-term survival in SCLC

05 May 2022 by

Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

Adding durvalumab upfront to chemo ups long-term survival in SCLC

05 May 2022

Physical pain highly prevalent among patients with psychiatric illness

05 May 2022 by

Most patients with psychiatric illness sustain physical pain, and they perceive pain differently, according to a Singapore study.

Physical pain highly prevalent among patients with psychiatric illness

05 May 2022

Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers

05 May 2022

The stools of asymptomatic patients carry the most common viruses that cause gastroenteritis in children and serve as a potential reservoir for acute gastroenteritis (AGE), a study has shown.

Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers

05 May 2022

When is the best time to initiate peritoneal dialysis in ESKD patients?

05 May 2022 by

A planned start appears to be the best strategy for initiating peritoneal dialysis (PD) in patients with end-stage kidney disease (ESKD), but an early start is a good alternative if a planned start is not possible, suggests a Singapore study. In addition, catheter migration may be more frequent with early-start PD, but it does not seem to affect technique survival.

When is the best time to initiate peritoneal dialysis in ESKD patients?

05 May 2022

Which agent is safe, most effective for treating cutaneous polyarteritis nodosa?

05 May 2022

Use of colchicine provides a good balance between benefit and risk in patients with cutaneous polyarteritis nodosa without peripheral sensory neuropathy, reports a study. In the event of relapse, the best treatment appears to be the combination of glucocorticoids and azathioprine.

Which agent is safe, most effective for treating cutaneous polyarteritis nodosa?

05 May 2022

New data boost efficacy, safety of lower-sodium oxybate for idiopathic hypersomnia

05 May 2022 by

Lower-sodium oxybate – a new oxybate treatment with 92-percent less sodium than sodium oxybate – continued to demonstrate its potential in improving function, productivity, and sleepiness in individuals with idiopathic hypersomnia, according to data presented at AAN 2022.

New data boost efficacy, safety of lower-sodium oxybate for idiopathic hypersomnia

05 May 2022

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

New drug applications approved by US FDA as of 16-30 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

Wearable device tracks recovery after total knee replacement

05 May 2022 by

A novel wearable device can accurately measure range of motion (ROM) and gait in patients who had undergone total knee replacement (TKR), according to a recent study. This proposed system could facilitate portable progress monitoring in this population.

Wearable device tracks recovery after total knee replacement

05 May 2022

Newer fixed-dose ICS/LABA combos tied to greater adherence, less exacerbations in asthma

05 May 2022

Among fixed-dose combinations of inhaled corticosteroids/long-acting beta-2-adrenergic agonists (ICS/LABA), the newer combinations of fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM) are associated with increased treatment persistence and lead to fewer exacerbations among patients with asthma, as shown in a study.

Newer fixed-dose ICS/LABA combos tied to greater adherence, less exacerbations in asthma

05 May 2022

Prilocaine/lidocaine spray safe, effective in men with premature ejaculation

05 May 2022

The eutectic-like mixture of prilocaine/lidocaine spray appears to work well in the treatment of men with various types of premature ejaculation, as reflected by a high treatment adherence, according to data from a real-world study.

Prilocaine/lidocaine spray safe, effective in men with premature ejaculation

05 May 2022

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Adding durvalumab upfront to chemo ups long-term survival in SCLC

Adding durvalumab upfront to chemo ups long-term survival in SCLC

Physical pain highly prevalent among patients with psychiatric illness

Physical pain highly prevalent among patients with psychiatric illness

Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers

Viruses causing gastroenteritis in children thrive in stools of asymptomatic carriers

When is the best time to initiate peritoneal dialysis in ESKD patients?

When is the best time to initiate peritoneal dialysis in ESKD patients?

Which agent is safe, most effective for treating cutaneous polyarteritis nodosa?

Which agent is safe, most effective for treating cutaneous polyarteritis nodosa?

New data boost efficacy, safety of lower-sodium oxybate for idiopathic hypersomnia

New data boost efficacy, safety of lower-sodium oxybate for idiopathic hypersomnia

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Wearable device tracks recovery after total knee replacement

Wearable device tracks recovery after total knee replacement

Newer fixed-dose ICS/LABA combos tied to greater adherence, less exacerbations in asthma

Newer fixed-dose ICS/LABA combos tied to greater adherence, less exacerbations in asthma

Prilocaine/lidocaine spray safe, effective in men with premature ejaculation

Prilocaine/lidocaine spray safe, effective in men with premature ejaculation